282 related articles for article (PubMed ID: 20467757)
1. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Rozzi A; Nardoni C; Corona M; Restuccia MR; Fabi A; Bria E; Minniti G; Lanzetta G
Support Care Cancer; 2011 May; 19(5):697-701. PubMed ID: 20467757
[TBL] [Abstract][Full Text] [Related]
2. Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Matsuda M; Yamamoto T; Ishikawa E; Akutsu H; Takano S; Matsumura A
Neurol Med Chir (Tokyo); 2016 Nov; 56(11):698-703. PubMed ID: 27666343
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Lorusso V; Giampaglia M; Petrucelli L; Saracino V; Perrone T; Gnoni A
Support Care Cancer; 2012 Dec; 20(12):3241-6. PubMed ID: 22534864
[TBL] [Abstract][Full Text] [Related]
4. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
5. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
Lorusso V; Spedicato A; Petrucelli L; Saracino V; Giampaglia M; Perrone T
Support Care Cancer; 2009 Dec; 17(12):1469-73. PubMed ID: 19294429
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D
Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
[TBL] [Abstract][Full Text] [Related]
8. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
[TBL] [Abstract][Full Text] [Related]
9. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
Celio L; Bonizzoni E; Bajetta E; Sebastiani S; Perrone T; Aapro MS
Support Care Cancer; 2013 Feb; 21(2):565-73. PubMed ID: 22869054
[TBL] [Abstract][Full Text] [Related]
10. A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Aogi K; Sakai H; Yoshizawa H; Masuda N; Katakami N; Yanagita Y; Inoue K; Kuranami M; Mizutani M; Masuda N
Support Care Cancer; 2012 Jul; 20(7):1507-14. PubMed ID: 21808994
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials.
Popovic M; Warr DG; Deangelis C; Tsao M; Chan KK; Poon M; Yip C; Pulenzas N; Lam H; Zhang L; Chow E
Support Care Cancer; 2014 Jun; 22(6):1685-97. PubMed ID: 24590374
[TBL] [Abstract][Full Text] [Related]
13. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
14. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Miura S; Watanabe S; Sato K; Makino M; Kobayashi O; Miyao H; Iwashima A; Okajima M; Tanaka J; Tanaka H; Kagamu H; Yokoyama A; Narita I; Yoshizawa H
Support Care Cancer; 2013 Sep; 21(9):2575-81. PubMed ID: 23644992
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
[TBL] [Abstract][Full Text] [Related]
17. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Di Renzo N; Montanini A; Mannina D; Dondi A; Muci S; Mancuso S; De Paolis MR; Plati C; Stelitano C; Patti C; Olivieri A; Liardo E; Buda G; Cantaffa R; Federico M
Support Care Cancer; 2011 Oct; 19(10):1505-10. PubMed ID: 20694798
[TBL] [Abstract][Full Text] [Related]
18. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.
Navari RM
Future Oncol; 2006 Oct; 2(5):591-602. PubMed ID: 17026451
[TBL] [Abstract][Full Text] [Related]
19. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron: in the prevention of nausea and vomiting.
Yang LP; Scott LJ
Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
